Chapter 8 Atherogenic Lipoprotein Subprofiling

Allison A. Ellington, Iftikhar Jan Kullo

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Elevated levels of low-density lipoprotein (LDL) cholesterol are a major risk factor for coronary heart disease. However, a significant number of coronary events occur in individuals with "normal" serum LDL cholesterol levels. It has been proposed that coronary heart disease (CHD) risk stratification may be improved by evaluating LDL particle size and number and lipoprotein (a) [Lp(a)] levels in addition to LDL-associated cholesterol levels. This chapter includes a brief review of lipoprotein biology and presents an overview of the association between novel lipoprotein markers and CHD risk. We also discuss methodologies currently available for atherogenic lipid subprofiling.

Original languageEnglish (US)
Pages (from-to)295-317
Number of pages23
JournalAdvances in Clinical Chemistry
Volume46
DOIs
StatePublished - 2008

Fingerprint

LDL Cholesterol
Lipoproteins
Coronary Disease
LDL Lipoproteins
Lipoprotein(a)
Particle Size
Particle size
Cholesterol
Lipids
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Chemistry(all)

Cite this

Chapter 8 Atherogenic Lipoprotein Subprofiling. / Ellington, Allison A.; Kullo, Iftikhar Jan.

In: Advances in Clinical Chemistry, Vol. 46, 2008, p. 295-317.

Research output: Contribution to journalArticle

@article{c97d0b0a9ff44e9c9d0cc2bd13f7fee3,
title = "Chapter 8 Atherogenic Lipoprotein Subprofiling",
abstract = "Elevated levels of low-density lipoprotein (LDL) cholesterol are a major risk factor for coronary heart disease. However, a significant number of coronary events occur in individuals with {"}normal{"} serum LDL cholesterol levels. It has been proposed that coronary heart disease (CHD) risk stratification may be improved by evaluating LDL particle size and number and lipoprotein (a) [Lp(a)] levels in addition to LDL-associated cholesterol levels. This chapter includes a brief review of lipoprotein biology and presents an overview of the association between novel lipoprotein markers and CHD risk. We also discuss methodologies currently available for atherogenic lipid subprofiling.",
author = "Ellington, {Allison A.} and Kullo, {Iftikhar Jan}",
year = "2008",
doi = "10.1016/S0065-2423(08)00408-3",
language = "English (US)",
volume = "46",
pages = "295--317",
journal = "Advances in Clinical Chemistry",
issn = "0065-2423",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Chapter 8 Atherogenic Lipoprotein Subprofiling

AU - Ellington, Allison A.

AU - Kullo, Iftikhar Jan

PY - 2008

Y1 - 2008

N2 - Elevated levels of low-density lipoprotein (LDL) cholesterol are a major risk factor for coronary heart disease. However, a significant number of coronary events occur in individuals with "normal" serum LDL cholesterol levels. It has been proposed that coronary heart disease (CHD) risk stratification may be improved by evaluating LDL particle size and number and lipoprotein (a) [Lp(a)] levels in addition to LDL-associated cholesterol levels. This chapter includes a brief review of lipoprotein biology and presents an overview of the association between novel lipoprotein markers and CHD risk. We also discuss methodologies currently available for atherogenic lipid subprofiling.

AB - Elevated levels of low-density lipoprotein (LDL) cholesterol are a major risk factor for coronary heart disease. However, a significant number of coronary events occur in individuals with "normal" serum LDL cholesterol levels. It has been proposed that coronary heart disease (CHD) risk stratification may be improved by evaluating LDL particle size and number and lipoprotein (a) [Lp(a)] levels in addition to LDL-associated cholesterol levels. This chapter includes a brief review of lipoprotein biology and presents an overview of the association between novel lipoprotein markers and CHD risk. We also discuss methodologies currently available for atherogenic lipid subprofiling.

UR - http://www.scopus.com/inward/record.url?scp=53849134495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849134495&partnerID=8YFLogxK

U2 - 10.1016/S0065-2423(08)00408-3

DO - 10.1016/S0065-2423(08)00408-3

M3 - Article

VL - 46

SP - 295

EP - 317

JO - Advances in Clinical Chemistry

JF - Advances in Clinical Chemistry

SN - 0065-2423

ER -